Drug Type Antibody fusion proteins |
Synonyms- |
Target |
Action agonists, inhibitors |
Mechanism IL15R agonists(Interleukin-15 receptors agonists), PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | United States | 01 Jul 2021 | |
| Neoplasms | Preclinical | China | 01 Jul 2021 |






